RG
ORIC icon

Redmile Group’s Oric Pharmaceuticals ORIC Stock Holding History

Redmile Group’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.92M Sell
362,010
-53,700
-13% -$487K 0.26% 36
2026
Q1 		$5.27M Sell
415,710
-32,400
-7% -$368K 0.35% 29
2025
Q4 		$3.67M Buy
+448,110
New +$5.16M 0.27% 32

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Redmile Group's ORIC Position: Q2 2026 in Review

Redmile Group reduced its Oric Pharmaceuticals (ORIC) stake by 13% in Q2 2026, selling an estimated $487K and leaving 362,010 shares worth $3.92M. The position accounts for 0.26% of the portfolio, ranked #36.

Redmile Group first reported a position in ORIC in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.27M in Q1 2026. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Redmile Group held 362,010 shares of Oric Pharmaceuticals worth $3.92M as of Q2 2026.
  • Redmile Group sold 53,700 Oric Pharmaceuticals shares in Q2 2026, an estimated $487K.
  • Oric Pharmaceuticals made up 0.26% of Redmile Group's portfolio in Q2 2026, its #36 holding.
  • Redmile Group first reported a position in Oric Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Redmile Group's Oric Pharmaceuticals position peaked at $5.27M in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.